News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Applied Molecular Evolution (AMEV) To Present At CIBC World Markets Healthcare Conference November 10



10/19/2005 5:10:22 PM

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Applied Molecular Evolution, Inc. (AME) announced today that Dr. Lawrence E. Bloch, Chief Financial Officer of AME, will present an overview of the Company at the Fourteenth Annual CIBC World Markets Healthcare Conference on Monday, November 10, 2003 at 8:30 am ET.

The presentation will be webcast live and will be available via archive approximately three hours following the presentation at http://www.ame.biz/ .

About Applied Molecular Evolution

Applied Molecular Evolution, Inc. (AME) is a leader in applying directed molecular evolution to improve healthcare by optimizing and developing human biotherapeutics. Directed molecular evolution is a process for optimizing genes and proteins for specific commercial purposes. Since its inception, AME's principal focus has been on applying its proprietary AMEsystem(TM) technology platform to human biotherapeutics, the largest market for directed molecular evolution. Biotherapeutics, or biopharmaceuticals, are protein pharmaceuticals such as antibodies, cytokines, hormones and enzymes. AME uses its proprietary technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. For more information, please visit http://www.ame.biz/ .

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including uncertainties related to product development, uncertainties related to the need for regulatory or other government approvals, dependence on proprietary technology, uncertainty of market acceptance of the Company's products, uncertainties related to business opportunities, the receipt of future payments, including royalties, the continuation of customer relationships and other risks cited in the Company's Annual Report on Form 10-K for the year ended December 31, 2002, and other SEC Filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

For further information, please contact, Chris Erdman of Applied Molecular Evolution, +1-858-638-8635.

Applied Molecular Evolution

CONTACT: Chris Erdman of Applied Molecular Evolution, +1-858-638-8635


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES